Free shipping on all orders over $ 500
  Catalog
Abmole Inhibitor Catalog 2017

Src-bcr-Abl Src-bcr-Abl

Inhibitors

Cat.No.  Name Information
M5916 Radotinib Radotinib is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia.
M5553 Dasatinib Monohydrate Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
M5552 Dasatinib HCl Dasatinib(BMS-354825) hydrochloride is a potent and dual Abl/ Src inhibitor IC50 of <1 nM/0.8 nM respectively; also inhibit c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
M5251 MCB-613 MCB-613 is a potent steroid receptor coactivator (SRC) stimulator.
M5190 GNF-7 GNF-7 is the first type II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design next generation Bcr-Abl kinase inhibitors.
M4843 SU6656 SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
M3778 PF-562771 PF-562771 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth.
M3676 WH-4-023 WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM, respectively.
M2953 PP1 PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
M2917 PD173955 PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.
M2749 GZD824 GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
M2603 GNF-5 GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).
M2571 GNF-2 GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.
M2331 PP2 PP2 is a selective inhibitor of Src-family tyrosine kinases with >10,000-fold selectivity over ZAP-70 and JAK2.
M2313 KX2-391 KX2-391 (KX01) is a highly selective non ATP-competitive Src inhibitor with GI50 of 9-60 nM in cancer cell lines .
M1991 Bafetinib Bafetinib (NS-187, INNO-406) is a novel second-generation dual Bcr-Abl/Lyn tyrosine kinase inhibitor.
M1912 Nilotinib Nilotinib (AMN107) is a small molecule Bcr-Abl kinase inhibitor with IC50 less than 30 nM.
M1825 PCI-32765 PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM.
M1799 Imatinib Mesylate Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively.
M1712 FTY720 FTY720 (Fingolimod) is a sphingosine-1-phosphate receptor 1 receptor.
M1702 DCC-2036 DCC-2036 is an ABL inhibitor with IC50 of 0.8 and 2 nM for u-ABL1native and p-ABL1native, respectively.
M1701 Dasatinib Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively.
M1685 Bosutinib Bosutinib (SKI-606) is a novel Bcr-Abl inhibitor with IC50 values of 0.1 to 0.3 umol/L.
M1659 Saracatinib Saracatinib (AZD0530) is an orally active small molecule Src inhibitor.
M1648 AP24534 Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor of BCR-ABL, PDGFRα, c-Src, c-Kit, FGFR and VEGFR.


Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.